Skip to main navigation Skip to search Skip to main content

Randomized phase II study of nivolumab (N) alone versus with pegilodecakin (PEG) in combination with N in patients (pts) with post-platinum immunotherapy-naive stage IV non-small cell lung cancer (NSCLC) and no or low PD-L1 expression (CYPRESS 2).

  • Robert M. Jotte
  • , Jerome H. Goldschmidt
  • , Jeffrey Gary Schneider
  • , Merrill Kingman Shum
  • , David Berz
  • , Lasika C. Seneviratne
  • , Matei P. Socoteanu
  • , Annie Hung
  • , Rebecca R. Hozak
  • , Bo H. Chao
  • , John J. Nemunaitis
  • US Oncology Research and Rocky Mountain Cancer Centers, Denver, CO;
  • Oncology and Hematology Assoc of SW Virginia, Blacksburg, VA;
  • NYU Winthrop Hospital, Mineola, NY;
  • The Onc Inst of Hope and Innovation, Whittier, CA;
  • Beverly Hills Cancer Center, Beverly Hills, CA;
  • Los Angeles Cancer Network, Los Angeles, CA;
  • Texas Oncology
  • Eli Lilly and Company
  • Gradalis, Inc., Dallas, TX;

Research output: Contribution to journal › Article › peer-review

Original languageAmerican English
JournalJournal of Clinical Oncology
Volume38
DOIs
StatePublished - May 25 2020
Externally publishedYes

Disciplines

  • Medicine and Health Sciences
  • Oncology

Cite this